A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Nivolumab (Primary) ; T lymphocyte cell therapies (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.
- 18 Aug 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
- 14 Jul 2017 New trial record